Moderna statement to Axios
“Moderna has a broad owned and licensed IP estate covering key aspects of its platform. This estate
provides multiple layers of protection covering the making and use of the mRNA drug substance and
delivery technologies, including LNP-encapsulated mRNA coding for infectious disease antigens for use
in prophylactic vaccination, including mRNA-1273. We are not aware of any IP that would prevent us
from commercializing our product candidates, including mRNA-1273.”